Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer

被引：0
|
作者：
Imase, R. [1 ]
Endo, S. [1 ]
Sasahara, Y. [1 ]
Shinmura, T. [1 ]
Ozawa, T. [1 ]
Majima, H. [1 ]
Hara, T. [1 ]
Shimada, H. [1 ]
Yamauchi, S. [1 ]
Sakakibara, Y. [1 ]
Kobayashi, A. [1 ]
Yamazaki, K. [1 ]
Jin, Y. [1 ]
Yamanaka, K. [1 ]
Matsubara, O. [1 ]
机构：
[1] Hiratsuka Kyosai Hosp, Hiratsuka, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
ALK tyrosine kinase inhibitors; crizotinib; Alectinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.03-010
引用
收藏
页码：S1953 / S1953
页数：1
相关论文
共 50 条
  • [1] An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer
    Ai, Xinghao
    Shen, Shengping
    Shen, Lan
    Lu, Shun
    [J]. BIOCHIMIE, 2015, 112 : 111 - 120
  • [2] SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Barrows, S. M.
    Wright, K.
    Copley-Merriman, C.
    Kaye, J. A.
    Chioda, M. D.
    Wiltshire, R.
    Torgersen, K. M.
    Masters, E. T.
    [J]. VALUE IN HEALTH, 2018, 21 : S49 - S50
  • [3] Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
    Wang, Li
    Wang, Wen
    [J]. ONCOLOGY REPORTS, 2021, 45 (01) : 13 - 28
  • [4] Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer
    Yu, Yongfeng
    Ou, Qiuxiang
    Wu, Xue
    Bao, Hairong
    Ding, Yan
    Shao, Yang W.
    Lu, Shun
    [J]. LUNG CANCER, 2019, 127 : 19 - 24
  • [5] Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort
    Bedas, Aseel
    Peledc, Nir
    Rabinovich, Natalie Maimon
    Mishaeli, Moshe
    Shochat, Tzippy
    Zer, Alona
    Rotem, Ofer
    Allen, Aaron M.
    Bar, Jair
    Dudnik, Elizabeth
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) : 275 - 282
  • [6] Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
    Singh, Abhay
    Chen, Hongbin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6615 - 6628
  • [7] Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer
    Liu, Jingru
    Ma, Shutao
    [J]. CURRENT MEDICINAL CHEMISTRY, 2017, 24 (06) : 590 - 613
  • [8] Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers
    Kinoshita, Kazutomo
    Oikawa, Nobuhiro
    Tsukuda, Takuo
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47, 2012, 47 : 281 - 293
  • [9] Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
    Vavala, Tiziana
    Mariniello, Annapaola
    Novello, Silvia
    [J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S48 - S54
  • [10] The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
    Fan, Junsheng
    Fong, Tszhei
    Xia, Zengfei
    Zhang, Jian
    Luo, Peng
    [J]. CANCER MEDICINE, 2018, 7 (10): : 4993 - 5005
12345